News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) and Cardiovascular Research Foundation Initiate Phase 3 Clinical Trial with Ranolazine in Patients Who Have Undergone PCI with a History of Prior Chronic Angina


11/7/2011 8:08:35 AM

FOSTER CITY, Calif. & NEW YORK--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI). RIVER-PCI will enroll 2,600 patients at approximately 200 investigative centers in the United States, Canada, Europe and Israel.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES